All > Hereditary Angioedema > Spokane

KVD900 600 mg for Hereditary Angioedema

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Hereditary AngioedemaKVD900 600 mg - Drug
Eligibility
12 - 17
All Sexes
What conditions do you have?
Select

Study Summary

This trial is looking at how a new drug affects teenagers with Hereditary Angioedema.

Eligible Conditions
  • Hereditary Angioedema

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Similar Trials

1
STAR-0215
1
VAD044
1
ASC61 600 mg

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: Up to 6 hours after IMP administration

Hour 6
Pharmacokinetics - AUC
Pharmacokinetics - Cmax
Pharmacokinetics - Tmax

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Similar Trials

1
STAR-0215
1
VAD044
1
ASC61 600 mg

Trial Design

1 Treatment Group

KVD900 600 mg
1 of 1

Experimental Treatment

12 Total Participants · 1 Treatment Group

Primary Treatment: KVD900 600 mg · No Placebo Group · Phase 3

KVD900 600 mg
Drug
Experimental Group · 1 Intervention: KVD900 600 mg · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 6 hours after imp administration

Who is running the clinical trial?

KalVista Pharmaceuticals, Ltd.Lead Sponsor
9 Previous Clinical Trials
737 Total Patients Enrolled
Study DirectorStudy DirectorKalVista Pharmaceuticals, Ltd.
1,070 Previous Clinical Trials
475,566 Total Patients Enrolled

Eligibility Criteria

Age 12 - 17 · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You must provide a legally authorized representative (LAR) when you are 18 years or older.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top